2024 AUA preview: Dr. Wymer on top research in stone disease
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
In this video, Kevin M. Wymer, MD, discusses 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Wymer is an assistant professor of urology at Mayo Clinic in Rochester, Minnesota.
The following abstracts were previewed:
1. MP43-10 (Vergamini et al) Intrarenal Pressure and Flow Rate Profile Using Lithovue EliteTM: Impact of Different Irrigation Systems and Working Channel Use
2. MP04-02 (Chartier et al): Ureteroscopic Techniques and Anatomic Sites Associated with Periods of Elevated Intrarenal Pressure
3. MP29-15 (Liu et al): Clinical results of the first disposable intrarenal pressure measuring flexible ureteroscope in China
4. PD10-04 (Matlaga et al): Prospective, randomized study of steerable ureteroscopic renal evacuation vs ureteroscopy with basketing: 30-day results of the ASPIRE study
5. PD10-09 (Lakmichi et al): 24 hours after retrograde intrarenal surgery for solitary renal calculi using a flexible and navigable suction access sheath (FANS): Results from a prospective global multicentre study by the EAU section on urolithiasis (EULIS)
6. MP40-07 (Pate et al): Claims-Based Approach to Defining Episodes of Care Associated with Acute Renal Colic
7. MP57-17 (Dwyer et al): MyUrology Health: Implementation of a Novel Episode Based Payment Model for Nephrolithiasis
8. MP45-02 (Maciolek et al): Evaluation of an Automated CT-Based Deep Learning Image Segmentation Model for Stone Characterization in Difficult-to-Image Situations
9. MP45-03 (Cheng et al): Comparison Of A Machine-Learning Model versus Endourologists in Accurately Predicting Stone Composition from Endoscopic Video Data
10. MP29-11 (Holmes et al): Feasibility of burst wave lithotripsy and ultrasonic propulsion to expel small, asymptomatic renal stones
11. MP29-09 (Amiel et al): The Magnetic Force: SRF Extraction in Living Porcine Models
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
